ABVX
ABIVAX Société Anonyme
ABIVAX Société Anonyme (ABVX) Q1 2026 earnings
Published May 22, 2026
AI summary
- Revenue €1.3M, up 30% from €1.0M a year ago.
- Abivax reported an operating loss of 56.2 million euros for the first quarter of 2026.
- Total operating income for the quarter was 1.3 million euros, up from 1.0 million euros in the prior year.
- Research and development expenses rose to 49.5 million euros, driven by obefazimod clinical programs.
- The company ended the quarter with 491.6 million euros in cash and short-term investments.
Results vs analyst consensus
Revenue
Reported
€1.3M
Consensus not captured before release
+30% YoY
EPS
Not reported in this release.
Consensus: Yahoo Finance · Q1 2026
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- The company is in the clinical stage and continues to report significant operating losses.
- Future cash runway is dependent on current operating assumptions.
Read original report
Source: ABIVAX Société Anonyme press release · SEC Form 6-K exhibit 99.1